Laurus Labs is an integrated research and development driven pharmaceutical and biotechnology company in India.
Corporate office - Banjara Hills, Hyderabad.
Brief history / Key events
- 2005 - Laurus Labs was started.
- 2016 - Successfully launched their IPO.
- 2021 - Richcore Lifesciences was acquired and renamed as Laurus Bio (subsidiary of Laurus Labs).
Market overview
- The world's population is set to continue to rise, with aged people population expected to double in 2050 and make up almost 16% of population.
- The increasing aged population and changes in lifestytes could lead to increase in chronic non communicable diseases such as heart diseases, cancer and diabetics.
- Due to improved economic situation and urbanisation, people are better informed and avail access to medicines and surgical procedures.
- Global pharmaceutical manufacturing is expected to grow at CAGR 13.74% in the period 2020-27.
- India fulfills 20% of global demand for generic medicines in terms of volume.
- India also supplies over 60% of global demand for various vaccines and Antiretroviral (ARV) drugs.
- Indian generics industry can benefit substantially from the patent cliff as patents for branded molecules (worth global sales of more than $ 251 billion) are expected to expire between 2018 and 2024.
- Supply disruption from China: Chinese players have been forced to shift their manufacturing facilities inland and outside the cities as the government continues to crack down on polluting industries.
- There is also an increasing preference to reduce dependency on China for API products.
- Competitiveness of Chinese players would reduce to a certain extent going forward as their cost of production increases.
- Moreover, the Covid pandemic has forced governments to de-risk their supply chains by on-shoring and strengthening domestic capabilities.
- To increase competition in the market, US FDA has significantly ramped up the pace of product approvals under the Generic Drug User Fee Act (GDUFA). The increased competition has led to significant price erosion impacting per product economics in the market. On the other hand, this will also help pharma companies in getting faster approvals and expanding their portfolio offering.
Product mix / business segments of Laurus Labs
- Laurus Labs started their journey from an ARV API company to API company and now to a full blown pharma company.
- T
hello! yes, i know this is yet another, “do you know where i can find” post, but srsly - there are many gardeners here, so... my son and i have looked in so many places for bay leaf laurel plants (he wants to use them for cooking and also to make laurel crowns, because of course [he’s a bit of a dandy]).
most nurseries only carry Prunus lusitanica, which is slightly unsuitable for the purpose as it contains cyanide (i mean, depending on what your family dinners are like, perhaps it is suitable? 🤔)
we’ve mostly looked on the peninsula so far, but are getting a bit discouraged. if anyone knows of places that carry bay leaf plants, that would be greatly appreciated. thank you so much!! 🙇🏻
I’ve been unable to find info on this. Don’t know if it’s a very popular herb in other countries but it’s one I like to use in the kitchen, so if anyone has any idea if it’s low fodmap, I’d really appreciate
I just lost a game to a guy with a level 5 laurus, it was so broken. I had an 11 strength unit bordered by and 8, 7, and 5 strength unit. He took out 31 of my units and got his 10 strength unit on the board. Maybe have 1 unit attack instead of all, or at least lower the strength. Rant over
I have seen for Eicher Motors that on the day of split the price rises dramatically followed by a fall in next few days. But not sure if it will happen for sure.
Question is to buy on the day of split or after few days? Pharma is madly rising, hence the fomo.
P.S - This is for mid to long term. I am a poor man, Yolo jitne paise nai hai 😅
Laurus Labs is an integrated research and development driven pharmaceutical and biotechnology company in India.
Corporate office - Banjara Hills, Hyderabad.
Brief history / Key events
- 2005 - Laurus Labs was started.
- 2016 - Successfully launched their IPO.
- 2021 - Richcore Lifesciences was acquired and renamed as Laurus Bio (subsidiary of Laurus Labs).
Market overview
- The world's population is set to continue to rise, with aged people population expected to double in 2050 and make up almost 16% of population.
- The increasing aged population and changes in lifestytes could lead to increase in chronic non communicable diseases such as heart diseases, cancer and diabetics.
- Due to improved economic situation and urbanisation, people are better informed and avail access to medicines and surgical procedures.
- Global pharmaceutical manufacturing is expected to grow at CAGR 13.74% in the period 2020-27.
- India fulfills 20% of global demand for generic medicines in terms of volume.
- India also supplies over 60% of global demand for various vaccines and Antiretroviral (ARV) drugs.
- Indian generics industry can benefit substantially from the patent cliff as patents for branded molecules (worth global sales of more than $ 251 billion) are expected to expire between 2018 and 2024.
- Supply disruption from China: Chinese players have been forced to shift their manufacturing facilities inland and outside the cities as the government continues to crack down on polluting industries.
- There is also an increasing preference to reduce dependency on China for API products.
- Competitiveness of Chinese players would reduce to a certain extent going forward as their cost of production increases.
- Moreover, the Covid pandemic has forced governments to de-risk their supply chains by on-shoring and strengthening domestic capabilities.
- To increase competition in the market, US FDA has significantly ramped up the pace of product approvals under the Generic Drug User Fee Act (GDUFA). The increased competition has led to significant price erosion impacting per product economics in the market. On the other hand, this will also help pharma companies in getting faster approvals and expanding their portfolio offering.
Product mix / business segments of Laurus Labs
- Laurus Labs started their journey from an ARV API company to API company and now to a full blown pharma company.
- T
can anyone explain me this all laurus labs hype...i am 17 so it’s all new to me.
